In this article, we will look at the 10 Small–Cap Stocks Insiders Are Buying Recently.
Insider buying tends to get attention for the simple reason that executives and directors usually know their own businesses better than outside investors do. That does not make every purchase a guaranteed win, but it can matter when insiders are buying after a stretch of weak sentiment or market overreaction. That signal can be even more interesting in small caps, where information gaps tend to be wider, and price swings can be sharper. Insider buying often offers a clue that management may see a disconnect between the current share price and the company’s underlying prospects.
That rationale shows up in how professional investors describe their own process. J.P. Morgan Asset Management says its Undiscovered Managers Behavioral Value Fund seeks to “capitalize on behavioral biases” and looks for “companies with significant insider buying or stock repurchases,” along with “evidence of overreaction that has caused devaluation” and “attractive fundamentals.” Meanwhile, Franklin Templeton, in its Value Balanced Portfolios factsheet, says it emphasizes companies with “healthy balance sheets” trading at “prices that do not accurately reflect cash flows, tangible assets or management skills.” It also says managers may “Re-examine a current holding” when “there is unusual insider buying/selling.” Taken together, these suggest insider transactions are treated as one of the signals professionals watch when they think the market may be mispricing a stock.
With that in mind, we will look at the 10 Small-Cap Stocks Insiders Are Buying Recently.
Our Methodology
We used the Finviz stock screener to identify small-cap companies with a significant increase in insider ownership over the last six months. We then limited our final selection to stocks that have recently reported noteworthy developments likely to influence investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. ACV Auctions Inc. (NYSE:ACVA)
On March 19, 2026, ACV Auctions Inc. (NYSE:ACVA) announced the launch of ACV MAX Recommendations, an AI-powered feature within its ACV MAX suite designed to “deliver profit-focused guidance” on vehicle pricing. The company said the tool provides recommendations based on real-time data, dealership history, and individual VINs, with Ryan Walker noting it removes “guesswork” and reduces decision bottlenecks while maintaining dealer control.
Last month, Barrington analyst Gary Prestopino upgraded ACV Auctions Inc. (NYSE:ACVA) to Outperform from Market Perform with a $7-$9 price target range, describing the recent share selloff as “unwarranted” and expecting adjusted EBITDA growth to recover in 2026. Gary Prestopino added that there were no major concerns in the Q4 report and said expectations had been too aggressive.
Meanwhile, Citi analyst Ronald Josey downgraded ACV Auctions Inc. (NYSE:ACVA) to Neutral from Buy with a price target of $7, down from $13, citing slower-than-expected share gains and a more challenging macro environment, while noting that benefits from new initiatives may not materialize until the second half of 2026 and into 2027.
ACV Auctions Inc. (NYSE:ACVA) operates a wholesale auction marketplace for business-to-business used vehicle sales between dealerships.
9. Biohaven Ltd. (NYSE:BHVN)
On March 19, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in a Phase 2 proof-of-concept study of taldefgrobep alfa, a myostatin-activin pathway inhibitor aimed at achieving weight loss in people with obesity. The company expects topline data in the second half of 2026.
On March 11, 2026, TD Cowen analyst Ken Cacciatore raised the price target on Biohaven Ltd. (NYSE:BHVN) to $30 from $15 and maintained a Buy rating. Ken Cacciatore updated the model following validation of the Kv7 mechanism of action in focal epilepsy based on azetukalner data and said this supports expectations ahead of topline opakalim data expected mid-year, while noting potential to highlight a differentiated CNS adverse event profile.
Earlier in March, Biohaven Ltd. (NYSE:BHVN) reported Q4 adjusted EPS of (90c), compared to the (96c) consensus estimate. CEO Vlad Coric said the company made “significant progress” advancing its pipeline, highlighting its degrader platform as a “central pillar” of strategy and pointing to early evidence demonstrating the ability to target disease mechanisms while preserving immune function, supporting confidence in the platform’s potential.
Biohaven Ltd. (NYSE:BHVN) develops therapies across immunology, neuroscience, and oncology.
